Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD

References

• Weiss G Hechtman L Milroy T Perlman T Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children J Am Acad Child Psychiatry 1985 24 2 211 220 3989165
   PubMedGoogle Scholar
• Davidson MA ADHD in adults: a review of the literature J Atten Disord 2008 11 6 628 641 18094324
   PubMed Web of Science ®Google Scholar
• Polanczyk G Rohde LA Epidemiology of attention-deficit/hyperactivity disorder across the lifespan Curr Opin Psychiatry 2007 20 4 386 392 17551354
   PubMed Web of Science ®Google Scholar
• Simon V Czobor P Bálint S Mészáros A Bitter I Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis Br J Psychiatry 2009 194 3 204 211 19252145
   PubMed Web of Science ®Google Scholar
• Biederman J Faraone SV Spencer TJ Mick E Monuteaux MC Aleardi M Functional impairments in adults with self-reports of diagnosed ADHD: A controlled study of 1001 adults in the community J Clin Psychiatry 2006 67 4 524 540 16669717
   PubMed Web of Science ®Google Scholar
• Barkley RA Grodzinsky G DuPaul GJ Frontal lobe functions in attention deficit disorder with and without hyperactivity: a review and research report J Abnorm Child Psychol 1992 20 2 163 188 1593025
   PubMed Web of Science ®Google Scholar
• Clark C Prior M Kinsella GJ Do executive function deficits differentiate between adolescents with ADHD and oppositional defiant/conduct disorder? A neuropsychological study using the Six Elements Test and Hayling Sentence Completion Test J Abnorm Child Psychol 2000 28 5 403 414 11100915
   PubMed Web of Science ®Google Scholar
• Greenhill LL Pliszka S Dulcan MK Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults J Am Acad Child Adolesc Psychiatry 2001 40 11 1352 1355 11699811
   PubMed Web of Science ®Google Scholar
• Faraone SV Spencer TJ Kollins SH Glatt SJ Goodman D Dose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory study J Atten Disord 2012 16 2 118 127 21527575
   PubMed Web of Science ®Google Scholar
• Mordre M Groholt B Sandstad B Myhre AM The impact of ADHD symptoms and global impairment in childhood on working disability in mid-adulthood: a 28-year follow-up study using official disability pension records in a high-risk in-patient population BMC Psychiatry 2012 12 174 23083209
   PubMed Web of Science ®Google Scholar
• Castells X Ramos-Quiroga JA Rigau D Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis CNS Drugs 2011 25 2 157 169 21254791
   PubMed Web of Science ®Google Scholar
• Castells X Ramos-Quiroga JA Bosch R Nogueira M Casas M Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults Cochrane Database Syst Rev 2011 6 CD007813 21678370
   PubMed Web of Science ®Google Scholar
• Blick SK Keating GM Lisdexamfetamine Paediatr Drugs 2007 9 2 129 135 discussion 136–138 17407369
   PubMedGoogle Scholar
• Elbe D Macbride A Reddy D Focus on lisdexamfetamine: A review of its use in child and adolescent psychiatry J Can Acad Child Adolesc Psychiatry 2010 19 4 303 314 21037922
   PubMedGoogle Scholar
• Madaan V Kolli V Bestha DP Shah MJ Update on optimal use of lisdexamfetamine in the treatment of ADHD Neuropsychiatr Dis Treat 2013 9 977 983 23901276
   PubMed Web of Science ®Google Scholar
• Adler LA Goodman DW Kollins SH 303 Study Group Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder J Clin Psychiatry 2008 69 9 1364 1373 19012818
   PubMed Web of Science ®Google Scholar
• Faraone SV Lisdexamfetamine dimesylate: the first long-acting prodrug stimulant treatment for attention deficit/hyperactivity disorder Expert Opin Pharmacother 2008 9 9 1565 1574 18518785
   PubMed Web of Science ®Google Scholar
• Wigal T Brams M Gasior M Gao J Squires L Giblin J 316 Study Group Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design Behav Brain Funct 2010 6 34 20576091
   PubMed Web of Science ®Google Scholar
• Biederman J Fried R Hammerness P The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire J Adolesc Health 2012 51 6 601 607 23174471
   PubMed Web of Science ®Google Scholar
• Dupaul GJ Weyandt LL Rossi JS Double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in college students with ADHD J Atten Disord 2012 16 3 202 220 22166471
   PubMed Web of Science ®Google Scholar
• Adler LA Dirks B Deas PF Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study J Clin Psychiatry 2013 74 7 694 702 23945447
   PubMed Web of Science ®Google Scholar
• Higgins JPT Altman DG Sterne JAC Assessing risk of bias in included studies Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 The Cochrane Collaboration 2009 [updated March 2011]. Available from: http://www.cochrane-handbook.org Accessed August 3, 2014
   Google Scholar
• Cipriani A Furukawa TA Salanti G Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis Lancet 2009 373 9665 746 758 19185342
   PubMed Web of Science ®Google Scholar
• Papakostas GI Tolerability of modern antidepressants J Clin Psychiatry 2008 69 Suppl E1 8 13 18494538
   PubMed Web of Science ®Google Scholar
• Wiebe N Vandermeer B Platt RW Klassen TP Moher D Barrowman NJ A systematic review identifies a lack of standardization in methods for handling missing variance data J Clin Epidemiol 2006 59 4 342 353 16549255
   PubMed Web of Science ®Google Scholar
• Sterne JAC Egger M Moher D Addressing reporting biases Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 The Cochrane Collaboration 2009 [updated March 2011]. Available from: http://www.cochrane-handbook.org Accessed August 3, 2014
   Google Scholar
• Lasser R Dirks B Adeyi B Babcock T Comparative efficacy and safety of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in adults with attention-deficit/hyperactivity disorder Primary Psychiatry 2010 17 9 44 54
   Google Scholar
• Surman CB Roth T Impact of stimulant pharmacotherapy on sleep quality: post hoc analyses of 2 large, double-blind, randomized, placebo-controlled trials J Clin Psychiatry 2011 72 7 903 908 21824454
   PubMed Web of Science ®Google Scholar
• Mattingly GW Weisler RH Young J Clinical response and symptomatic remission in short- and long-term trials of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder BMC Psychiatry 2013 13 39 23356790
   PubMed Web of Science ®Google Scholar
• Brams M Weisler R Findling RL Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design J Clin Psychiatry 2012 73 7 977 983 22780921
   PubMed Web of Science ®Google Scholar
• Retz W Rösler M Ose C Study Group Multiscale assessment of treatment efficacy in adults with ADHD: a randomized placebo-controlled, multi-centre study with extended-release methylphenidate World J Biol Psychiatry 2012 13 1 48 59 21155632
   PubMed Web of Science ®Google Scholar
• Biederman J Mick E Surman C A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder J Clin Psychopharmacol 2010 30 5 549 553 20814332
   PubMed Web of Science ®Google Scholar
• Casas M Rösler M Sandra Kooij JJ Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study World J Biol Psychiatry 2013 14 4 268 281 22106853
   PubMed Web of Science ®Google Scholar
• Biederman J Monuteaux MC Doyle AE Impact of executive function deficits and attention-deficit/hyperactivity disorder (ADHD) on academic outcomes in children J Consult Clin Psychol 2004 72 5 757 766 15482034
   PubMed Web of Science ®Google Scholar
• Fallu A Richard C Prinzo R Binder C Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder Curr Med Res Opin 2006 22 12 2557 2566 17166338
   PubMed Web of Science ®Google Scholar
• Brown TE Holdnack J Saylor K Effect of atomoxetine on executive function impairments in adults with ADHD J Atten Disord 2011 15 2 130 138 20026871
   PubMed Web of Science ®Google Scholar
• Castells X Cunill R Capellà D Treatment discontinuation with methylphenidate in adults with attention deficit hyperactivity disorder: a meta-analysis of randomized clinical trials Eur J Clin Pharmacol 2013 69 3 347 356 22983311
   PubMed Web of Science ®Google Scholar
• ehealthme.com [homepage on the Internet] Could Vyvanse cause stress cardiomyopathy? eHealthMe 2014 [cited May 25, 2014]. Available from: http://www.ehealthme.com/ds/vyvanse/stresscardiomyopathy Accessed August 3, 2014
   Google Scholar